EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis

Sahar Israeli Dangoor iD, Rami Khoury, Koren Salomon, Sabina Pozzi, Shir Shahar, Adan Miari, Yael Leichtmann-Bardoogo, Neta Bar-Hai, Neta Frommer, Eilam Yeini, Tom Winkler, Nora Balint Lahat und 11 weitere

Brain · 2025

DOI: 10.1093/brain/awae347 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, 2025. Verfasst von Sahar Israeli Dangoor und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel. Hauptthemen laut MEDLINE: Chemokine CCL2, Brain Neoplasms, Breast Neoplasms, P-Selectin. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: European Research Council, ERC Proof of Concept, The Israel Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Over the last two decades, the diagnosis and treatment of breast cancer patients have improved considerably. However, brain metastases remain a major clinical challenge and a leading cause of mortality. Thus, a better understanding of the pathways involved in the metastatic cascade is essential. To this end, we have investigated the reciprocal effects of astrocytes and breast cancer cells, employing traditional 2D cell culture and our unique 3D multicellular tumouroid models. Our findings revealed that astrocytes enhance the proliferation, migration and invasion of breast cancer cells, suggesting a supportive role for astrocytes in breast cancer outgrowth to the brain. Elucidating the key players in astrocyte-breast cancer cells crosstalk, we found that CCL2 is highly expressed in breast cancer brain metastases tissue sections from both patients and mice. Our in vitro and in vivo models further confirmed that CCL2 has a functional role in brain metastasis. Given their aggressive nature, we sought additional immune checkpoints for rationale combination therapy. Among the promising candidates were the adhesion molecule P-selectin, which we have recently shown to play a key role in the crosstalk with microglia cells and the co-inhibitory receptor PD-1, the main target of currently approved immunotherapies. Finally, combining CCL2 inhibition with immunomodulators targeting either PD-1/PD-L1 or P-selectin/P-Selectin Ligand-1 axes in our human 3D tumouroid models and in vivo presented more favourable outcomes than each monotherapy. Taken together, we propose that CCL2-CCR2/CCR4 is a key pathway promoting breast cancer brain metastases and a promising target for an immunotherapeutic combination approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CCL2Brain NeoplasmsBreast NeoplasmsP-SelectinProgrammed Cell Death 1 ReceptorImmunologic FactorsAnimalsFemaleHumansMiceCell Line, TumorAstrocytesCell Movement

Stichwörter der Autor:innen

3D cancer modelsCCL2P-selectinPD-1astrocytesbreast cancer brain metastasis

Substanzen

Chemokine CCL2CCL2 protein, humanP-SelectinProgrammed Cell Death 1 ReceptorPDCD1 protein, humanImmunologic Factors

Autor:innen und Institutionen

  • Department of Physiology and Pharmacology, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Biomedical Engineering, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Cancer Research Center, Oncology Institute, Sheba Medical Center, Tel-Hashomer 5262000, Israel.
  • Affiliated with Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Human Molecular Genetics and Biochemistry, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel.
  • Department of Pathology, Sheba Medical Center, Tel Hashomer 5262000, Israel.

ORCID-Profile: Sahar Israeli Dangoor, Iris Barshack, Ben M Maoz, Ronit Satchi-Fainaro

Förderung

  • European Research Council
  • ERC Proof of Concept
  • The Israel Science Foundation
  • Israel Cancer Research Fund
  • Morris Kahn Foundation
  • La Caixa Banking Foundation
  • Health Research BBM- Breast Cancer Brain Metastasis

Zitieren

APA

Israeli Dangoor, S., Khoury, R., Salomon, K., Pozzi, S., Shahar, S., Miari, A., Leichtmann-Bardoogo, Y., Bar-Hai, N., Frommer, N., Yeini, E., Winkler, T., Balint Lahat, N., Kamer, I., Hadad, O., Laue, K., Brem, H., Hyde, T. M., Bar, J., Barshack, I., …, & Satchi-Fainaro, R. (2025). CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis. Brain. https://doi.org/10.1093/brain/awae347

Vancouver

Israeli Dangoor S, Khoury R, Salomon K, Pozzi S, Shahar S, Miari A, et al. CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis. Brain. 2025. doi:10.1093/brain/awae347

BibTeX
@article{IsraeliDangoor2025,
  author = {Israeli Dangoor, Sahar and Khoury, Rami and Salomon, Koren and Pozzi, Sabina and Shahar, Shir and Miari, Adan and Leichtmann-Bardoogo, Yael and Bar-Hai, Neta and Frommer, Neta and Yeini, Eilam and Winkler, Tom and Balint Lahat, Nora and Kamer, Iris and Hadad, Ori and Laue, Kathrin and Brem, Henry and Hyde, Thomas M and Bar, Jair and Barshack, Iris and Ben-David, Uri and Ishay-Ronen, Dana and Maoz, Ben M and Satchi-Fainaro, Ronit},
  title = {CCL2 blockade combined with PD-1/P-selectin immunomodulators impedes breast cancer brain metastasis},
  journal = {Brain},
  year = {2025},
  doi = {10.1093/brain/awae347}
}
Kostenlos starten →